DOI: 10.36347/sasjs.2021.v07i11.011

Pages: 688-691

Medication-related osteonecrosis of the jaw (MRONJ) is a well-known complication of antiresorptive treatments and was first described with bisphosphonate treatment and recently with denosumab, and other anti-angiogenic drugs. It has been reported that MM patients have the highest risk of MRONJ mainly in patients who received combination of pamidronate and zoledronate. Neither clinical nor radiologic features are pathognomonic for MRONJ, in fact bone metastasis may have overlapping characteristics and must be excluded in histologic examination. We report a case of a multiple myeloma patient treated with zoledronic acid and whose initial clinical presentation was challenging to distinguish between bone metastasis and MRONJ.